This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial
that is designed to test whether treating patients who are at risk for development of lupus
with hydroxychloroquine can slow accumulation of disease features. Effects on clinical
progression of symptoms, patient-reported outcomes and changes in the immune markers of
response will be measured and toxicity of the treatment will be assessed. This trial is a
first step in testing a prevention strategy for lupus.